Targacept NNR Drug Development Is Smokin’ After GSK Cash Infusion
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo partners with Targacept in potential $1.5 billion deal on neuronal nicotinic receptor therapeutics for pain, smoking cessation, obesity, addiction and Parkinson’s.
You may also be interested in...
Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.
Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.
Targacept/GSK’s Nicotinic Receptor Modulator Fails Phase II Pain Study
Experimental pain killer performed no better than placebo, failing a proof-of-concept study for post-operative pain.